Available clinical evidences suggest that CD34+ selection reduces myeloma contamination in PBSC (Peripheral Blood Stem Cell) collections [5,6,24,25], however, it does not eliminate it, and it does not improve disease-free or overall survival of transplanted patients [8,9,26]. The gene discussed is CD34; the disease is plasma cell myeloma.